13th Annual Global Embolization Symposium & Technologies
Purpose : The aim of this study was to report our experience about BAE with CalliSpheres drug-eluting beads in a consecutive group of patients with cancer and hemoptysis that required BAE and to evaluate retrospectively the efficacy and safety of the technique
Material and Methods : From Mar 2015 to Oct 2017, a BAE was performed on 42 patients with hemoptysis with one vial of 300-500μm CalliSpheres drug-eluting beads (Gemcitabine 100mg). The control group consisted of 50 men who were treated with polyvinyl alcohol (PVA) at 355-500 μm. We categorized the results as technical and clinical successes, and also included the mid-term results. Technical success was defined as the complete cessation of the target artery as confirmed by digital subtraction angiography (DSA). Clinical success was defined as the cessation of haemoptysis within 24 h of BAE. Technical success was compared immediately after the procedure. The clinical success and mid-term results (percentage of patients who were free of hemoptysis) were compared at 1 and 12 months after the procedure, respectively.
Results : There was no significant difference for technical successes (DEB group: 90%, PVA group: 85%, P>0.05). However, the clinical successes (DEB group: 83.3%, PVA group: 68%, P<0.01) and the mid-term results (DEB group: 71.4%, PVA group: 64%, P<0.01) showed a significant difference. Moreover, Disease control rate (CR+PR+SD) was higher in DEB group than PVA group (DEB group: 78.5%, PVA group: 48%, P<0.01). The procedure-related complications included mild cough and mild chest pain. There was no special management required for these complications.
Conclusions : Drug-eluting beads appears to be the more optimal modality compared to PVA particles for bronchial artery embolization in order to improve the mid-term results.